Free Trial
NYSE:DNA

Ginkgo Bioworks (DNA) Stock Price, News & Analysis

$0.30
0.00 (0.00%)
(As of 07/24/2024 ET)
Today's Range
$0.29
$0.34
50-Day Range
$0.28
$0.85
52-Week Range
$0.26
$2.54
Volume
36.14 million shs
Average Volume
66.24 million shs
Market Capitalization
$669.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.40

Ginkgo Bioworks MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.67 Rating Score
Upside/​Downside
362.4% Upside
$1.40 Price Target
Short Interest
Healthy
8.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Ginkgo Bioworks in the last 14 days
Based on 4 Articles This Week
Insider Trading
Balanced
Insiders Both Buying and Selling
Proj. Earnings Growth
Growing
From ($0.30) to ($0.22) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.73 out of 5 stars

Medical Sector

390th out of 901 stocks

Biological Products, Except Diagnostic Industry

53rd out of 152 stocks

DNA stock logo

About Ginkgo Bioworks Stock (NYSE:DNA)

Ginkgo Bioworks Holdings Inc. is a biotech company attempting to revolutionize the biotechnology industry by engineering completely new organisms. Founded in 2008 by Jason Kelly, Austin Che, Thomas Knight Jr. and Bartholomew Canton, the company operates a market-agnostic platform utilizing the latest technologies to pioneer the development of more sustainable biotechnology and bioengineering applications. 

Ginkgo Bioworks Holdings Inc. develops multiple platforms for food production, agriculture, industrial and pharmaceuticals. These platforms enable bioengineering applications across diverse markets, and the company customizes organisms for customers ranging from large companies to smaller startups. The company also creates proprietary software, algorithms and automation to engineer "customizable organisms" for their customers and the development of new products for the industrial and consumer markets. 

The company has earned multiple awards for its innovative technology in biologics, including the National Science Foundation's Innovation Corps Award, the National Academy of Engineering's Grand Challenges Award and the World Economic Forum's Technology Pioneers Award. 

Ginkgo Bioworks Holdings Inc. has partnered with prestigious organizations, including the Broad Institute of MIT, Harvard, Genomics England, the National Institutes of Health and the National Science Foundation's Innovation Corps to further their mission of making biotechnology more accessible to smaller and medium-sized organizations. 

Ginkgo Bioworks Holdings Inc. strives to revolutionize the biotech industry, attempting to pioneer the development of an ecosystem that will provide more sustainable and accessible biotechnology systems. With the help of innovative technology and strategic partnerships with prestigious organizations, Ginkgo Bioworks Holdings Inc. is well on its way to achieving this goal and making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. has a market cap of approximately $2.97 billion, down from $3.98 in 2022. However, the company has seen rapid growth since 2020, increasing revenues from $3.8 million in 2017 to $313.8 million in 2022. 

DNA Stock Price History

DNA Stock News Headlines

Ginkgo Bioworks (NYSE:DNA) Shares Gap Up to $0.28
Biden Pushing To Replace The Dollar With a Digital Coin, Control Currency.
Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.
Ginkgo Bioworks Holdings Inc - Class A
Ginkgo Bioworks (NYSE:DNA) Shares Gap Up to $0.29
Biden Pushing To Replace The Dollar With a Digital Coin, Control Currency.
Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.
3 Stocks to Avoid Like the Plague in 2024
Ginkgo Bioworks Layoffs Expand to 400 Job Cuts
See More Headlines
Receive DNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
7/25/2024
Next Earnings (Estimated)
8/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Fax
N/A
Employees
1,218
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.40
High Stock Price Target
$3.00
Low Stock Price Target
$0.20
Potential Upside/Downside
+362.4%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
6 Analysts

Profitability

Net Income
$-892,870,000.00
Net Margins
-409.11%
Pretax Margin
-409.17%

Debt

Sales & Book Value

Annual Sales
$251.46 million
Book Value
$0.55 per share

Miscellaneous

Outstanding Shares
2,211,280,000
Free Float
1,878,481,000
Market Cap
$669.58 million
Optionable
Optionable
Beta
1.14
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

DNA Stock Analysis - Frequently Asked Questions

How have DNA shares performed this year?

Ginkgo Bioworks' stock was trading at $1.69 at the beginning of 2024. Since then, DNA shares have decreased by 82.1% and is now trading at $0.3028.
View the best growth stocks for 2024 here
.

How were Ginkgo Bioworks' earnings last quarter?

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). The firm had revenue of $37.94 million for the quarter, compared to analysts' expectations of $45.50 million. Ginkgo Bioworks had a negative net margin of 409.11% and a negative trailing twelve-month return on equity of 56.09%.

Who are Ginkgo Bioworks' major shareholders?

Ginkgo Bioworks' top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.11%). Insiders that own company stock include Reshma P Shetty, Barry Canton, Marijn E Dekkers, Jason R Kelly, Christian O Henry, Mark E Dmytruk, Steven P Coen and Marie E Fallon.
View institutional ownership trends
.

How do I buy shares of Ginkgo Bioworks?

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:DNA) was last updated on 7/25/2024 by MarketBeat.com Staff

From Our Partners